Cincinnati Doctor Leads NIH-Funded Trial to Target CMD in ANOCA Patients

Dr. Odayme Quesada in Cincinnati has secured a $3.6 million NIH grant to lead the nation’s first clinical trial of a treatment for CMD in ANOCA. The five‑year study will test the diabetes/heart failure drug dapagliflozin against a placebo in 120 men and women, enrolling at The Christ Hospital Health Network with University of Cincinnati researchers as collaborators; enrollment is expected to begin fall 2026.